Sterling Pharma Solutions launches £11 million Material Science Centre
The new centre will allow the company to improve efficiencies and reduce overall manufacturing time.
After announcing the investment last year, global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has officially opened its new multi-million-pound Material Science Centre (MSC).
The three-floor MSC comprises six ISO Class 8 cleanrooms, which house four milling and micronisation suites.
The new facility also contains warehousing and workshop facilities dedicated to the milling operations, as well as a new fully equipped solid state laboratory and an analytical services laboratory and write up area.
According to the company's CEO, Kevin Cook, the centre will provide a range of specialist solid state chemistry and milling services to complement the services it already provides.
Previously, the company outsourced its solid form services to third parties. Now, in response to customer requirements, Sterling Pharma Solutions has brought them in-house.
"The centre will allow us to manage more of the product processing and as a result improve efficiencies; mitigating risk and allowing us to provide our customers with more cost-effective solutions. It will also help to reduce overall manufacturing time as we continue to develop more efficient processes, said Mr Cook.
The CDMO's solid form development team will be housed within the facility and will work to optimise existing processes across four connected areas of solid form investigation including, salt/cocrystal screening, polymorph screening, preformulation evaluation and crystallisation development.
As a result of the ongoing pandemic and visitor restrictions, Sterling will be launching the centre virtually. This will include a webinar hosted by Sterling’s experts to introduce the facility, team and services.
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc... -
News Key takeaways from Saudi Arabia's National Biotechnology Strategy
In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance